嘉乐健康
20-99人
公司优势

20,861+ 岗位更新等你来订阅
一键订阅最新的岗位,每周送达
🎉恭喜你,订阅成功
继续订阅您可以在邮箱中随时取消订阅
**南商(中国)有限公司招聘公告**
南商(中国)有限公司,作为中国信达资产管理股份有限公司的全资附属外商独资商业银行,是中国信达集团构建跨境综合金融服务体系的关键一环,总部位于上海,并已在全国多个城市如北京、上海、广州、深圳、汕头、青岛、杭州、无锡、成都、南宁、海口、大连、合肥、苏州等地设立了分支机构。公司秉承「服务专业,区域卓越」的愿景,致力于通过创新与专业化提升核心竞争力。
**加入我们,共创未来!**
**岗位招募信息**
因业务发展需求,现面向社会公开招募优秀人才。南商(中国)提供广阔的职业发展空间与专业系统培训,期待您的加入。
**申请材料提交指南**
请将以下资料寄至本行人力资源部:
- **个人简历**:请详细填写并注明联系方式(包括电话、电子邮件、地址及邮编)。
- **证件/证书复印件**:
- 身份证/护照
- 学历/学位证书
- 英语等级证书
- 专业资格证书
- 专业技术职称证书
- 成果鉴定证书等
- **近期免冠照片**一张。
**邮寄地址**:浙江省杭州市上城区新业路200号华峰国际大厦28-29楼,邮编:310000。请在信封上清晰标注应聘岗位名称。
**注意事项**:
- 符合条件者,公司将通过邮件或电话通知后续甄选流程。
- 未被录用人员的申请材料恕不退还,请自行保留副本。
**携手南商(中国),共赴金融事业的辉煌旅程!**
我们是一家外资企业,专注于生产和制造POS收款机、触摸一体机、工业机以及现金抽屉等产品。
IMPACT Therapeutics is a biopharmaceutical company dedicated to the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality. The company has built one of the most comprehensive DNA damage response (DDR) pipelines of novel drug candidates generated through its own research efforts and is expanding into additional novel synthetic lethality targets.
The company's pipeline includes PARP inhibitors (senaparib/IMP4297), Wee1 inhibitors (IMP7068), and other DDR pathway inhibitors. The lead clinical program, PARP inhibitor (senaparib/IMP4297), is in Phase II/III studies for ovarian cancer, prostate cancer, small cell lung cancer, and other indications globally, including China. Early clinical data for senaparib have shown superior tolerability and a wider therapeutic window compared to other PARP inhibitors. A Phase I study of Wee1 inhibitor (IMP7068) is being conducted globally. The Hedgehog pathway inhibitor (IMP5471) has received IND approval from the National Medical Products Administration (NMPA) to initiate clinical studies in China.
Founded and managed by an experienced team from the global pharmaceutical industry, the company has established a complete early-stage research and clinical development organization that has expanded to the United States. The company has received investments from reputable venture capital firms such as Lilly Asia Ventures and strategic investor JunShi Biosciences.
四川腾龙石油输气防腐有限公司,作为西南油气田集输工程技术研究所的托管单位,同时也是四川华油集团有限责任公司的全资子公司,成立于1996年6月18日,注册为一家有限责任公司,注册资本金为500万元。该公司的主要业务包括:新建管道的PCM检测服务、在役管道防腐层的检查与维护、绝缘层修复、输气管网缺陷的强化处理、阴极保护施工及系统检测、以及站场外部的防腐工作。
工作轻松,每月休息3天,包吃包住,有生日福利。